Clinical trials: Stage IIIC Breast Cancer AJCC v7
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
This randomized phase II trial studies how well tamoxifen citrate works compared with z-endoxifen hydrochloride in treating patients with breast cancer that has spread to nearby tissue or lymph nodes or other parts of the body…
- Conditions
- Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7
- Trial name
- NCT02311933
- Testing
- Endoxifen Hydrochloride, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 559 sites in United States
- Volunteers
- 81 people
- Sponsor
- National Cancer Institute (NCI)
Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative
Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery
This phase II trial studies how well radiation therapy works in treating post-menopausal women with early stage breast cancer undergoing surgery. Radiation therapy uses high energy x rays to kill tumor cells.
- Conditions
- Ductal Breast Carcinoma In Situ, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative
- Trial name
- NCT01754519
- Testing
- Therapeutic Conventional Surgery, Radiation Therapy, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Roswell Park Cancer Institute
Breast Cancer
A Phase III Randomized Trial of Metformin vs Placebo in Early Stage Breast Cancer
This study is looking at whether Metformin, an agent that is commonly used to treat diabetes, can decrease or affect the ability of breast cancer cells to grow and whether Metformin will work with other therapies to keep cancer…
- Trial name
- NCT01101438
- Testing
- metformin hydrochloride
- Where
- 344 sites in United States, Canada and 2 more
- Volunteers
- 3,649 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Abraxane and Lapatinib in Treating Patients With Stage I, Stage II, or Stage III Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as Abraxane, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00331630
- Testing
- lapatinib ditosylate, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwestern University
Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma
A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors
This phase II trial studies cediranib maleate in combination with olaparib in treating patients with solid tumors that have spread to other parts of the body (advanced/metastatic) or cannot be removed by surgery (unresectable)…
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
- Trial name
- NCT02498613
- Testing
- 18F-Fluoromisonidazole, Cediranib Maleate, Laboratory Biomarker Analysis
- Where
- 16 sites in United States, Canada
- Volunteers
- 122 people
- Sponsor
- National Cancer Institute (NCI)
Breast Carcinoma In Situ, Breast Ductal Carcinoma In Situ
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
This randomized phase I trial studies the side effects and best dose of endoxifen hydrochloride in treating participants who are undergoing breast surgery. Endoxifen hydrochloride may treat or reduce the risk of breast cancer.
- Conditions
- Breast Carcinoma In Situ, Breast Ductal Carcinoma In Situ, Breast Lobular Carcinoma In Situ, Stage I Breast Cancer AJCC v7
- Trial name
- NCT03317405
- Testing
- Endoxifen Hydrochloride, Questionnaire Administration
- Where
- 3 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Menopausal Symptoms
Studying Blood Samples From Women With Breast Cancer or Ductal Carcinoma In Situ Who Are Receiving Tamoxifen
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about differences in DNA and predict how well patients will respond to treatment and plan better treatment.
- Trial name
- NRR (NCT00764322)
- Testing
- tamoxifen citrate, gene expression analysis, pharmacogenomic studies
- Where
- 7 sites in United States
- Volunteers
- 501 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Breast Adenocarcinoma, HER2/Neu Negative
Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer
This randomized phase III trial studies how well eribulin mesylate or paclitaxel work as first- or second-line therapy in treating patients with stage IIIC-IV breast cancer that has come back.
- Conditions
- Breast Adenocarcinoma, HER2/Neu Negative, Invasive Breast Carcinoma, Stage IIIC Breast Cancer AJCC v7
- Trial name
- NCT02037529
- Testing
- Eribulin Mesylate, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 39 sites in United States
- Volunteers
- 201 people
- Sponsor
- Academic and Community Cancer Research United
Breast Cancer
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00665457
- Testing
- filgrastim, capecitabine, celecoxib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Nebraska
Breast Cancer
Letrozole in Preventing Breast Cancer in Postmenopausal Women
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. Letrozole may be effective in preventing the development or recurrence of breast cancer in postmenopausal…
- Trial name
- WISE (NCT00090857)
- Testing
- Letrozole
- Where
- 5 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dana-Farber Cancer Institute
Estrogen Receptor Negative, Estrogen Receptor Positive
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
This randomized phase III trial studies the side effects and how well different chemotherapy regimens with or without bevacizumab work in treating patients with stage IIIC or stage IV breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT00785291
- Testing
- Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis
- Where
- 704 sites in United States, Puerto Rico
- Volunteers
- 799 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Depression
Yoga or Educational Wellness Class for Women With Stage I, Stage II, or Stage III Breast Cancer Undergoing Chemotherapy
RATIONALE: Yoga and wellness classes may reduce fatigue and improve mood, sleep, and quality of life in women receiving chemotherapy for breast cancer.
- Conditions
- Breast Cancer, Depression, Fatigue, Sleep Disorders
- Trial name
- NCT00994279
- Testing
- Yoga, Education
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Wake Forest University Health Sciences
HER2/Neu Positive, Progesterone Receptor Positive
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
This randomized phase III clinical trial studies chemotherapy with or without trastuzumab after surgery to see how well they work in treating women with invasive breast cancer.
- Conditions
- HER2/Neu Positive, Progesterone Receptor Positive, Recurrent Breast Carcinoma, Stage IA Breast Cancer AJCC v7
- Trial name
- NCT01275677
- Testing
- Cyclophosphamide, Docetaxel, Doxorubicin
- Where
- 1,283 sites in United States, Canada and 2 more
- Volunteers
- 3,270 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Sorafenib and Fulvestrant in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Aromatase Inhibitor Therapy
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Estrogen can cause the growth of breast cancer cells.
- Trial name
- NCT00722072
- Testing
- fulvestrant, sorafenib tosylate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- OHSU Knight Cancer Institute
Breast Cancer
Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer
RATIONALE: Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00847171
- Testing
- allogeneic GM-CSF-secreting breast cancer vaccine, trastuzumab, cyclophosphamide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
This phase II clinical trial studies how well omega-3 fatty acid works in treating patients with stage I-III breast cancer. Studying samples of tissue and blood in the laboratory from breast cancer patients receiving omega-3…
- Conditions
- Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ, Male Breast Cancer, Stage IA Breast Cancer
- Trial name
- NCT01869764
- Testing
- omega-3 fatty acid, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Wake Forest University Health Sciences
Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7
Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
This randomized phase III trial studies paclitaxel and trastuzumab with or without lapatinib to see how well they work in treating patients with stage II or stage III breast cancer that can be removed by surgery.
- Conditions
- Male Breast Carcinoma, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7, Stage IIIA Breast Cancer AJCC v7
- Trial name
- NCT00770809
- Testing
- Laboratory Biomarker Analysis, Lapatinib Ditosylate, Paclitaxel
- Where
- 318 sites in United States, Puerto Rico
- Volunteers
- 305 people
- Sponsor
- National Cancer Institute (NCI)
HER2/Neu Negative, No Evidence of Disease
Vaccine Therapy in Preventing Cancer Recurrence in Patients With Non-Metastatic, Node Positive, HER2 Negative Breast Cancer That is in Remission
This phase I trial studies the side effects and best dose of a vaccine therapy in preventing cancer from coming back in patients with non-metastatic, node positive, human epidermal growth factor receptor (HER)2 negative breast…
- Conditions
- HER2/Neu Negative, No Evidence of Disease, One or More Positive Axillary Nodes, Stage IB Breast Cancer
- Trial name
- WOKVAC (NCT02780401)
- Testing
- Laboratory Biomarker Analysis, pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine, Sargramostim
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
This randomized phase II trial studies how well fulvestrant works with or without bortezomib in treating patients with estrogen receptor positive breast cancer that has spread to other places in the body and cannot be removed by…
- Conditions
- Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
- Trial name
- NCT01142401
- Testing
- Bortezomib, Fulvestrant, Laboratory Biomarker Analysis
- Where
- 21 sites in United States
- Volunteers
- 118 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01547741
- Testing
- Doxorubicin, Cyclophosphamide, Docetaxel
- Where
- 915 sites in United States, Puerto Rico
- Volunteers
- 4,242 people
- Sponsor
- NSABP Foundation Inc